PMID- 16431875
OWN - NLM
STAT- MEDLINE
DCOM- 20060724
LR  - 20231024
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 27
IP  - 5
DP  - 2006 Mar
TI  - Long-term outcome with first-line bosentan therapy in idiopathic pulmonary 
      arterial hypertension.
PG  - 589-95
AB  - AIMS: Data on long-term efficacy of bosentan in unselected idiopathic pulmonary 
      arterial hypertension (IPAH) patients are lacking. We aimed to describe the 
      long-term outcome of consecutive IPAH patients treated first-line with bosentan. 
      METHODS AND RESULTS: A retrospective analysis of 103 consecutive New York Heart 
      Association functional class III/IV IPAH patients treated with bosentan at our 
      centre between November 1999 and May 2004 was performed. The 6-minute walk 
      distance (6MWD) and haemodynamics were assessed at baseline and after 4 and 12 
      months. Mean follow-up was 24+/-15 months. At 4 months, significant improvements 
      in exercise capacity and haemodynamics were observed and persisted up to 1 year. 
      Overall survival estimates were 90 and 87% and event-free status (survival 
      without transplantation, prostanoid initiation, or hospitalization for right 
      heart failure) estimates were 61 and 44% at 1 and 2 years, respectively. 
      Forty-five (44%) patients required prostanoid therapy during follow-up. The 6MWD 
      and the right atrial pressure at baseline and the 6MWD, the increase in 6MWD, and 
      the decrease in pulmonary resistance after 4 months of treatment were associated 
      with long-term outcomes. CONCLUSION: In our series of consecutive IPAH patients 
      treated with bosentan, improvements in exercise capacity and haemodynamics were 
      similar to those observed in previous randomized trials. However, on the basis of 
      local criteria, many patients required the addition of prostanoid therapy during 
      follow-up.
FAU - Provencher, Steeve
AU  - Provencher S
AD  - Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705), Service de 
      Pneumologie et Reanimation, AP-HP-Universite Paris-Sud, Hopital Antoine Beclere, 
      157 rue de la Porte de Trivaux, 92140 Clamart, France.
FAU - Sitbon, Olivier
AU  - Sitbon O
FAU - Humbert, Marc
AU  - Humbert M
FAU - Cabrol, Segolene
AU  - Cabrol S
FAU - Jais, Xavier
AU  - Jais X
FAU - Simonneau, Gerald
AU  - Simonneau G
LA  - eng
PT  - Journal Article
DEP - 20060123
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Sulfonamides)
RN  - Q326023R30 (Bosentan)
SB  - IM
CIN - Eur Heart J. 2006 Mar;27(5):510-1. PMID: 16459343
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Bosentan
MH  - Disease-Free Survival
MH  - Drug Therapy, Combination
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Hemodynamics
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/enzymology/mortality
MH  - Liver/enzymology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prostaglandins/therapeutic use
MH  - Retrospective Studies
MH  - Sulfonamides/*therapeutic use
MH  - Treatment Outcome
EDAT- 2006/01/25 09:00
MHDA- 2006/07/25 09:00
CRDT- 2006/01/25 09:00
PHST- 2006/01/25 09:00 [pubmed]
PHST- 2006/07/25 09:00 [medline]
PHST- 2006/01/25 09:00 [entrez]
AID - ehi728 [pii]
AID - 10.1093/eurheartj/ehi728 [doi]
PST - ppublish
SO  - Eur Heart J. 2006 Mar;27(5):589-95. doi: 10.1093/eurheartj/ehi728. Epub 2006 Jan 
      23.